Business
Calidi Biotherapeutics Announces Participation in RedChip’s April 16 Virtual Investor Conference to Feature Companies Advancing Clinical Pipelines and Scalable Healthcare Platforms
SAN DIEGO, April 15, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, will participate in RedChip’s upcoming virtual investor conference, “Biotech Resurgence: Platforms and Pipelines of Today’s Innovators,” taking place April 16, 2026, from 9:30 a.m. to 4:00 p.m. E.T. The full-day event will spotlight publicly traded companies advancing innovation across biote
About this update from Calidi Biotherapeutics, Inc.
[{"type":"image","alt":"Calidi Biotherapeutics, Inc","displaySize":"","headline":null,"caption":"Calidi Biotherapeutics, Inc","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":93,"url":"https://media.zenfs.com/en/globenewswire.com/8983e19176ab43568fb63e4ece5ad7a1"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/wX9t4eJfVQL9R1_CtWiapg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzMA--/https://media.zenfs.com/en/globenewswire.com/8983e19176ab43568fb63e4ece5ad7a1","width":300,"height":93}},"lazy":false},{"type":"text","content":"SAN DIEGO, April 15, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, will participate in RedChip’s upcoming virtual investor conference, “Biotech Resurgence: Platforms and Pipelines of Today’s Innovators,” taking place April 16, 2026, from 9:30 a.m. to 4:00 p.m. E.T.","length":406,"tagName":"p"},{"type":"text","content":"The full-day event will spotlight publicly traded companies advancing innovation across biotechnology, therapeutics, medical devices, diagnostics, and digital health. The conference will provide investors with direct access to executive leadership teams developing next-generation healthcare platforms, advancing clinical pipelines, and scaling commercial healthcare solutions.","length":377,"tagName":"p"},{"type":"text","content":"Registration is free and open to the public: https://www.redchip.com/webinar/redchip/84347130169","length":101,"tagName":"p"},{"type":"text","content":"RedTail is Calidi’s systemically delivered virotherapy platform designed to selectively target tumors, remodel the tumor microenvironment (TME), and enable high-level expression of therapeutic genetic payloads directly at the tumor site while limiting peripheral exposure. CLD-401, the lead candidate derived from the RedTail platform, is engineered to express high levels of IL-15 superagonist (IL-15 SA), a known T and NK-cell activator, in the TME. The Company expects to file an IND for CLD-401 by the end of 2026. Additionally, Calidi is expanding the RedTail platform to enable in situ expression of T-cell engagers (TCEs) in solid tumors, including in combination with T-cell activating payloads such as IL15 SA. This strategy is intended to support localized T-cell engageme...